SLC22A1 rs628031基因多态性与二甲双胍不良反应的关系  

The association of SLC22A1 rs628031 polymorphism with the adverse reaction of metformin

作　　者：陈培贤[1] 郭雅丽[2] 许琪[1] 陈大方[3] 王小竹[3] 张留伟[3] 刘志科[3] 黄东瑾[4] 倪伟锋[1] 陈慎仁[1] 

机构地区：[1]汕头大学医学院第二附属医院内分泌科,广东省515000 [2]中南大学湘雅二医院内分泌科 [3]北京大学医学部公共卫生学院 [4]汕头市中心医院内分泌科

出　　处：《中华临床医师杂志（电子版）》2014年第6期27-30,共4页Chinese Journal of Clinicians(Electronic Edition)

基　　金：广东省科技计划项目(2012B031800269);汕头市科技计划项目(汕府科[2012]113号)

摘　　要：目的本研究旨在观察SLC22A1 rs628031基因多态性与二甲双胍不良反应之间的关系。方法前瞻性研究93例接受单用二甲双胍口服降糖治疗的初诊2型糖尿病患者。从患者外周血白细胞中提取DNA,应用单碱基延伸法进行基因分型,并分析基因多态性与不同剂量二甲双胍不良反应的关系。结果 rs628031基因多态性与二甲双胍不良反应的发生,差异无统计学意义(P=0.062)。在药物剂量亚组分析中,rs628031 GA/AA基因型的患者接受单用高剂量二甲双胍口服降糖治疗后,发生不良反应的比率明显增高(85.7%vs.14.3%,P=0.015),但是,在低剂量组中,组间比较差异无统计学意义(P=0.605)。结论本研究结果提示SLC22A1 rs628031基因多态性与高剂量二甲双胍的不良反应发生有关。Objective To observe the association of SLC22A1 （solute carrier family 22, member1） rs628031 polymorphism with the adverse reaction of metformin. Methods We prospectively analyzed the clinical data from 93 patients with newly diagnosed type 2 diabetes mellitus who had received oral hypoglycemic treatment with different dose of metformin. Genomic DNA samples were extracted from the patients＇ leukocytes in the peripheral blood and the genotypes were determined by the SNaPshot method. The influence of the SLC22A1 rs628031 polymorphism on the adverse reaction was analyzed. Results We could not find a statistically significant association between gene polymorphism in the SLC22A1 rs628031 and the presence of the side effects of metformin（P=0.062）. From a subgroup analysis based on the dose of metformin, significant increases in the adverse reaction incidence were observed in patients who had the GA/AA genotype and had received the oral hypoglycemic treatment of high dose metformin（85.7%vs. 14.3%, P=0.015）. While there was no statistical significance in the low dose group（P=0.605）. Conclusion In this study, the results indicated that gene polymorphism in the SLC22A1 rs628031 increase the adverse reaction incidence of high dose of metformin.

关 键 词：糖尿病 2型 多态性 单核苷酸 二甲双胍 SLC22A1 不良反应 

分 类 号：R587.1[医药卫生—内分泌]